Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.
about
The role of the ALK receptor in cancer biologyTyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical ImplicationsOvercoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancerThe role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerManagement of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistanceTranslating cancer genomes and transcriptomes for precision oncologyThe distinctive nature of adenocarcinoma of the lungTreating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategyOvercoming resistance to targeted therapies in NSCLC: current approaches and clinical applicationGenetic instability in the tumor microenvironment: a new look at an old neighborPulmonary epithelioid inflammatory myofibroblastic sarcoma with multiple bone metastases: case report and review of literatureResistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategiesTumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesTrastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutationsTOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-JunRegistered report: Widespread potential for growth factor-driven resistance to anticancer kinase inhibitorsSrc inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.Controlling the Master: Chromatin Dynamics at the MYC Promoter Integrate Developmental SignalingThe correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.Molecular pathways and therapeutic targets in lung cancerThe peroxisome proliferator-activated receptor (PPAR) α agonist fenofibrate suppresses chemically induced lung alveolar proliferative lesions in male obese hyperlipidemic mice.In- and ex-vivo molecular imaging of apoptosis to assess sensitivity of non-small cell lung cancer to EGFR inhibitors using probe-based confocal laser endomicroscopy.Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.Emerging treatment for advanced lung cancer with EGFR mutation.Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitorsEGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond ProgressionMolecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyondProgression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical ModelsGenomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing.Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity ConsiderationsClinical potential of gene mutations in lung cancer.Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer.Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase InhibitorsPoorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitor.Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis
P2860
Q26738384-E3F601B0-6210-4A8D-B779-A5CB84B9F308Q26741318-9AF73068-8BBF-498D-B786-618EDB91B5ECQ26745427-42268C7B-DA09-4301-848B-22EE50AE0C29Q26749110-05CE1458-B412-4EB1-BC36-102CC775C370Q26775379-F24DEA2A-353D-4B7F-87DB-26FB1904F433Q26777081-0661F96D-2CA0-4510-B783-CD6819075920Q26781159-EE4CC78C-D0C8-4D3C-B09D-1B1CBFF38CD3Q26795555-DB1F9F7E-7320-4A65-B2BB-80DD1DD3A4A5Q26795556-C04007F3-2970-4025-8454-7DB8666389D1Q26801374-99C51FF2-F58E-415C-9D3F-06FED33CAEEAQ26823788-77B76B3D-1C30-4B7B-AC8C-CA045C7EEC53Q27004161-9D7B28A1-9C65-4D3C-A570-AF352E6D3F0DQ27014117-31EABC67-F9FC-428A-9958-0E25695ACC43Q27853015-836F6ACD-092D-4C53-81F8-C4C87C4C918CQ27853138-7FBE20A9-DB63-48B3-8617-8F25BCBAEAF5Q27853317-CCF1327F-3449-404D-8399-43AF6E402957Q28649561-1D2FC6C8-FFEB-4415-B028-E04BFEE610D1Q30278774-9B4C967A-E3DA-4509-A71D-6EC29547B00AQ30850656-2D424C01-C167-42F6-B57F-00A33CD6E69CQ33567383-0D51F986-D13A-4C3F-9E6A-D2795FD96B33Q33608508-6B8683F0-126A-4349-A63B-2B5A2A9F6D18Q33618747-867DBC23-957E-4C42-98A0-EB63756F5BFDQ33688872-B694485E-B2F2-4C8B-AFA6-CB5C589BE338Q33755975-01C93E3E-3867-4FB0-BE3D-158C939F5792Q33865965-D80CE2D1-8A94-443F-9438-87C8774578E8Q33873274-6A0DC7FF-260D-4E50-81A7-C576E6DADF6AQ34431889-06F1D9EB-20A2-4DB0-A7A6-A92F38C46F92Q34483953-649C285E-6566-4B77-A338-8F51C832519EQ34564071-D9BF0703-CAE2-4EFD-8342-612C2782D1FFQ34650994-4E97FDC3-1359-42A1-92A7-29C58E618BB4Q35256622-EA043E23-53B6-4B84-BBD7-35E4337A63F4Q35751883-1E7A573B-86CB-4CB5-8026-9CEAD5DDBC18Q35858617-0D4DB424-7D10-401F-B2AF-B822C7837828Q35979767-9CE816E4-2DA8-4FBE-8DC0-0DE15D833429Q36077810-1C3A0B42-52AA-401A-8B93-72206ADAA50FQ36316009-BE4C5E93-9B8A-43E1-AFDA-DC6FC7691488Q36414239-5B16F8B1-B3EB-4F1C-B23F-58C4CB475B5DQ36558400-B2864EE9-7836-4DB1-ABA0-86F1F642469EQ36710172-C935C496-696F-43F1-ACFE-45098371CD79Q36847104-479BA004-81C9-4D44-8AE9-BB4D57766607
P2860
Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Emerging paradigms in the deve ...... ase inhibitors in lung cancer.
@en
Emerging paradigms in the deve ...... ase inhibitors in lung cancer.
@nl
type
label
Emerging paradigms in the deve ...... ase inhibitors in lung cancer.
@en
Emerging paradigms in the deve ...... ase inhibitors in lung cancer.
@nl
prefLabel
Emerging paradigms in the deve ...... ase inhibitors in lung cancer.
@en
Emerging paradigms in the deve ...... ase inhibitors in lung cancer.
@nl
P2860
P356
P1476
Emerging paradigms in the deve ...... ase inhibitors in lung cancer.
@en
P2093
Alice T Shaw
Justin F Gainor
P2860
P304
P356
10.1200/JCO.2012.45.2029
P407
P577
2013-10-07T00:00:00Z